TNF-alpha and doxorubicin in hyperthermic perfusion for limb sarcomas

  • Authors:
    • C Rossi
    • M Foletto
    • A Vecchiato
    • N Menin
    • E Pizzirani
    • F Di Filippo
    • M Vaglini
    • M Santinami
    • A Azzarelli
    • R Cavaliere
    • M Lise
  • View Affiliations

  • Published online on: November 1, 1996     https://doi.org/10.3892/or.3.6.1059
  • Pages: 1059-1061
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Eighteen patients, subdivided into groups of three, were perfused for 90 min with escalating doses of TNF-alpha (0.5-3.3 mg) and standard doses of doxorubicin (bolus 0.7-1.4 mg/kg) at a tumor temperature of at least 41 degrees C, with the aim to ascertain the maximum tolerable dose (MTD) and the activity of TNF-alpha combined with doxorubicin in hyperthermic antiblastic perfusion (HAP) for patients with limb sarcomas, candidates for amputation. Tumor response was assessed both pathologically and radiologically. Severe systemic toxicity (WHO) was observed in only 2 patients. Locoregional toxicity (Wieberdink's) was grade I in 3 patients, grade II or III in 10 and grade IV in 5. A strict correlation between the TNF dosage and the grade of limb reaction was found, grade IV being retrieved only with TNF dose >1 mg and/or muscular temperature >41.5 degrees C. Tumor necrosis was evaluated in 16 patients: in 11 (68.8%) it scored more than 75% while in 5 it was 25 to 75%. Four cases (25%) had 100% tumor histological necrosis. Limb sparing surgery was feasible in 13 (81%). Our findings suggest that this is a well-tolerated and highly active regimen in HAP.

Related Articles

Journal Cover

November 1996
Volume 3 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Rossi C, Foletto M, Vecchiato A, Menin N, Pizzirani E, Di Filippo F, Vaglini M, Santinami M, Azzarelli A, Cavaliere R, Cavaliere R, et al: TNF-alpha and doxorubicin in hyperthermic perfusion for limb sarcomas. Oncol Rep 3: 1059-1061, 1996
APA
Rossi, C., Foletto, M., Vecchiato, A., Menin, N., Pizzirani, E., Di Filippo, F. ... Lise, M. (1996). TNF-alpha and doxorubicin in hyperthermic perfusion for limb sarcomas. Oncology Reports, 3, 1059-1061. https://doi.org/10.3892/or.3.6.1059
MLA
Rossi, C., Foletto, M., Vecchiato, A., Menin, N., Pizzirani, E., Di Filippo, F., Vaglini, M., Santinami, M., Azzarelli, A., Cavaliere, R., Lise, M."TNF-alpha and doxorubicin in hyperthermic perfusion for limb sarcomas". Oncology Reports 3.6 (1996): 1059-1061.
Chicago
Rossi, C., Foletto, M., Vecchiato, A., Menin, N., Pizzirani, E., Di Filippo, F., Vaglini, M., Santinami, M., Azzarelli, A., Cavaliere, R., Lise, M."TNF-alpha and doxorubicin in hyperthermic perfusion for limb sarcomas". Oncology Reports 3, no. 6 (1996): 1059-1061. https://doi.org/10.3892/or.3.6.1059